Cited 5 times in
Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2020-12-01T17:42:55Z | - |
dc.date.available | 2020-12-01T17:42:55Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180399 | - |
dc.description.abstract | Background and aims: Improvement in Model for End-Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)-related cirrhosis. We aimed to identify factors associated with transplant-free survival and on-treatment MELD score improvement. Methods: We identified patients with CHB-related cirrhosis and MELD score ≥ 15 at the start of entecavir and/or tenofovir disoproxil fumarate treatment between 2005 and 2017. The primary endpoint was transplant-free survival at month 6. The secondary endpoints at month 6 were transplant-free survival with > 5-point improvement in MELD score and transplant-free survival with MELD score < 15. Results: Of 999 cirrhotic CHB patients, 605 (60.6%) achieved transplant-free survival at month 6. Proportion of transplant-free survival at month 6 stabilized at 10% in patients with high MELD. Patients who achieved transplant-free survival at month 6 were younger, had lower MELD score, lower alanine aminotransferase (ALT), and higher albumin at baseline. Of 605 patients with transplant-free survival, 276 (45.6%) achieved > 5-point improvement in MELD score; 183 (30.2%) had 1-point to 5-point improvement in MELD score; 146 (24.1%) had no improvement or a worsened MELD score. Also, 321 (53.1%) patients with transplant-free survival had a MELD score < 15 at month 6. Conclusion: On top of lower MELD score, patients with CHB-related cirrhosis who are younger, have higher albumin, and lower ALT are more likely to achieve transplant-free survival after 6 months of antiviral treatment. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Alanine Transaminase / blood | - |
dc.subject.MESH | Antiviral Agents / therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Guanine / analogs & derivatives* | - |
dc.subject.MESH | Guanine / therapeutic use | - |
dc.subject.MESH | Hepatitis B, Chronic / complications | - |
dc.subject.MESH | Hepatitis B, Chronic / drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic / mortality* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis / drug therapy | - |
dc.subject.MESH | Liver Cirrhosis / etiology | - |
dc.subject.MESH | Liver Cirrhosis / mortality | - |
dc.subject.MESH | Liver Failure / etiology | - |
dc.subject.MESH | Liver Failure / prevention & control | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Research Design* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Serum Albumin | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Tenofovir / therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Terry Cheuk-Fung Yip | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Vincent Wai-Sun Wong | - |
dc.contributor.googleauthor | Grace Lai-Hung Wong | - |
dc.contributor.googleauthor | Yee-Kit Tse | - |
dc.contributor.googleauthor | Grace Chung-Yan Lui | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Henry Lik-Yuen Chan | - |
dc.identifier.doi | 10.1111/jgh.15007 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 32032974 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jgh.15007 | - |
dc.subject.keyword | MELD improvement | - |
dc.subject.keyword | liver cirrhosis | - |
dc.subject.keyword | transplant-free survival | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 35 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1610 | - |
dc.citation.endPage | 1618 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.35(9) : 1610-1618, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.